UCB plans big investment to expand US biologics manufacturing capacity

Belgium’s largest drugmaker UCB (Euronext: UCB) has announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the USA.

The company says the project is expected to serve UCB’s growing number of patients in the USA, while delivering a total estimated economic impact of approximately $5 billion. UCB is also continuing to scale up its partnerships with US contract manufacturing organizations (CMOs) to ensure the support for the production of its growth drivers and future pipeline.

UCB’s growing footprint in the USA reflects its long-term commitment to delivering scientific innovation, economic impact, and sustainable healthcare value. Since 2017, its US workforce has expanded by 73% to around 2,000 employees, underpinned by $4.5 billion in acquisitions and capital investments that have strengthened our innovation capabilities and infrastructure. Over this time, UCB has achieved 15 Food and Drug Administration (FDA) approvals or indication expansions - eight of which came in just the past two years - delivering meaningful advances in care for people living with severe diseases.